Fundraising Fox

Velsera

Founded 2023 · 427 employees on LinkedIn · 4 known investors

Velsera provides technology-enabled products and services for precision medicine, including the Seven Bridges platform for genomic research, data harmonization, and clinical next-generation sequencing (NGS) workflows. It serves pharmaceutical companies, life sciences researchers, and clinical diagnostic labs to accelerate drug development, genetic testing, and patient data analysis.

AI & Machine LearningBiotechDigital Health

Investors · 4

Health Catalyst CapitalNew York
OrbiMedNew York · $1M – $75M
SJF VenturesDurham · $1M – $10M
Summa EquityreportedStockholm

In the news

Velsera Is Building an Ecosystem that Accelerates the R&D Loop and Democratizes Omics Data to Propel the Next Era of Precision Medicine – enlightenbio Blogenlightenbio.com · Mar 2023Pierian, Seven Bridges, UgenTec Acquired, Merged to Become Velsera | GenomeWebgenomeweb.com · Jan 2023

Frequently asked questions

What does Velsera do?
Velsera provides technology-enabled products and services for precision medicine, including the Seven Bridges platform for genomic research, data harmonization, and clinical next-generation sequencing (NGS) workflows. It serves pharmaceutical companies, life sciences researchers, and clinical diagnostic labs to accelerate drug development, genetic testing, and patient data analysis.
Who are Velsera's investors?
Velsera's investors include Health Catalyst Capital, OrbiMed, SJF Ventures, Summa Equity.